Literature DB >> 26777209

Monophasic and biphasic shock for transthoracic conversion of atrial fibrillation: Systematic review and network meta-analysis.

José Francisco Secorun Inácio1, Michele dos Santos Gomes da Rosa2, Julie Shah3, Jeferson Rosário4, João Ricardo Nickenig Vissoci5, André Luiz Langer Manica6, Clarissa Garcia Rodrigues6.   

Abstract

OBJECTIVES: Conduct a systematic review of the literature to compare the efficacy of different biphasic and monophasic shock waveforms technologies for transthoracic cardioversion of Atrial Fibrillation (AF).
METHODS: We searched PubMed, EMBASE, The Cochrane Library, LILACS and ClinicalTrials.gov databases for randomized clinical trials comparing two or more defibrillation waveforms when performing elective transthoracic cardioversion of AF. The outcomes assessed were 1st shock success, overall success, cumulative energy and number of shocks to restore Normal Sinus Rhythm.
RESULTS: Were included 23 trials involving 3046 patients, 5 biphasic and the monophasic waveform. Direct meta-analysis revealed that Biphasic waveforms have higher chance to achieve cardioversion in the 1st shock (OR: 3.2; 95% CI 2.2-4.7) and after a sequence of attempts (OR:2.4; 95% CI 1.5-3.9), requiring 296 less Joules (95% CI 356-237) and 0.74 less shocks (95%CI 1.03-0.44) when compared to Monophasic. Network meta-analysis showed no significant differences between the Biphasic technologies of PhysioControl ADAPTIV, Philips SMART and ZOLL Rectilinear, in any of the four outcomes.
CONCLUSION: The evidences points to a Biphasic waveform superiority over Monophasic to perform AF cardioversion, supporting current guidelines to use less energy when using a Biphasic defibrillator. It is suggested that the Biphasic defibrillators from PhysioControl ADAPTIV, Philips SMART and ZOLL Rectilinear have similar efficacy and the use of any of them may result in similar chances, energy and number of shocks to achieve successful AF cardioversion.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Biphasic defibrillator; Cardioversion; Monophasic defibrillator; Systematic review, Network meta-analysis

Mesh:

Year:  2016        PMID: 26777209     DOI: 10.1016/j.resuscitation.2015.12.009

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  5 in total

1.  Association between transthoracic impedance and electrical cardioversion success with biphasic defibrillators: An analysis of 1055 shocks for atrial fibrillation and flutter.

Authors:  Mouhannad M Sadek; Varsha Chaugai; Mark J Cleland; Timothy J Zakutney; David H Birnie; F Daniel Ramirez
Journal:  Clin Cardiol       Date:  2018-05-11       Impact factor: 2.882

2.  Cardioversion of Atrial Fibrillation and Flutter: Comparative Study of Pulsed vs. Low Energy Biphasic Truncated Exponential Waveforms.

Authors:  Delphine Lavignasse; Elina Trendafilova; Elena Dimitrova; Vessela Krasteva
Journal:  J Atr Fibrillation       Date:  2019-10-31

3.  The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis.

Authors:  Naqash J Sethi; Sanam Safi; Emil E Nielsen; Joshua Feinberg; Christian Gluud; Janus C Jakobsen
Journal:  Syst Rev       Date:  2017-03-06

4.  Orthogonal electrical cardioversion in atrial fibrillation refractory to biphasic shocks: a case series.

Authors:  Enrique Velázquez-Rodríguez; Hipólito Alfredo Pérez-Sandoval; Francisco Javier Rangel-Rojo
Journal:  Eur Heart J Case Rep       Date:  2020-11-14

5.  Investigating the efficacy of chest pressure for direct current cardioversion in atrial fibrillation: a randomised control trial protocol (Pressure-AF).

Authors:  David Ferreira; Philo Mikhail; Michael McGee; Andrew Boyle; Aaron Sverdlov; Maged William; Nicholas Jackson; Malcolm Barlow; James Leitch; Nicholas Collins; Thomas Ford; Bradley Wilsmore
Journal:  Open Heart       Date:  2021-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.